Jasper Therapeutics posts investor presentation on Kira merger, PIPE financing and immunology pipeline strategy

Jasper outlined a merger with Kira Pharmaceuticals in an all-stock deal, paired with a $132 million PIPE financing.

Fully diluted ownership split: legacy Jasper holders 6.68%, legacy Kira holders 49.86%, PIPE investors 43.46%; shares outstanding about 653,600,000.

Legacy Jasper holders are to receive a non-transferable CVR tied to up to $30 million if a briquilimab PRV is obtained by end-2028.

PIPE proceeds are earmarked for KP-104 Phase 2 renal data readouts, KP-104 Phase 3 start in PNH, and briquilimab pre-BLA work in SCID.

Kira out-licensed KP-301 and KP-402 to Mirador Therapeutics for a $12 million upfront, with additional potential milestones.